GSK will buy efimosfermin, a liver disease drug in late-stage trials, for up to $2 billion from U.S. biotechnology firm ...

British pharmaceutical giant GlaxoSmithKline announced Wednesday the acquisition of a drug under development to treat a ...

Discover a study that offers new insight into the link between frailty and steatotic liver disease in older adults.

The prevalence of steatotic liver disease (SLD) was 33.3% in older adults, whereas fibrosis was less prevalent. Low physical activity, multimorbidity, and other factors were strongly associated ...

New research reveals that semaglutide significantly improves liver health in MASH patients. A new study published in the New ...

With its purchase of Boston Pharmaceuticals' drug, GSK extends a streak of dealmaking it's undertaken to build a liver ...

Researchers at the University of Oklahoma report a hormone, FGF21, may reverse fatty liver disease by signaling the brain.

London: GSK plc and Boston Pharmaceuticals, a clinical stage biopharmaceutical company developing highly targeted therapies ...

Just a day after dropping a $625m cancer asset, GSK has inked a deal worth a potential $2bn to acquire Boston Pharmaceuticals ...

GSK will gain access to efimosfermin by acquiring Boston’s subsidiary BP Asset IX for $1.2bn upfront and up to $800m in ...

GSK acquires Boston Pharmaceuticals' efimosfermin for up to $2 billion, targeting liver diseases like MASH and ALD.